Revista Headache Medicine最新文献

Migraine treatment with biological therapies. The state of the art 用生物疗法治疗偏头痛。最先进的技术

Revista Headache Medicine Pub Date : 2023-09-30 DOI: 10.48208/headachemed.2023.28

Abouch Krymchantowski, Carla Jevoux, Raimundo Pereira Silva-Néto

{"title":"Migraine treatment with biological therapies. The state of the art","authors":"Abouch Krymchantowski, Carla Jevoux, Raimundo Pereira Silva-Néto","doi":"10.48208/headachemed.2023.28","DOIUrl":"https://doi.org/10.48208/headachemed.2023.28","url":null,"abstract":"Migraine is a highly prevalent and debilitating neurological disorder. Most patients do not receive a correct diagnosis and effective treatments. Apart of the few specialists and tertiary centers worldwide, the treatment of migraine is usually symptomatic and prevention, as well as treatments of the underlying mechanisms, are not aimed. It results in frustration and substantial burden. The last few years witnessed the releasing of specific biological therapies, mostly addressing one of the peptides involved in migraine pathophysiology, the calcitonin gene-related peptide (CGRP). Either the small molecules as well as the monoclonal antibodies against CGRP or its canonical receptor have been launched in markets across the globe and represent interesting options for the treatment of migraine. Onabotulinumtoxin A has also been proposed for chronic migraine as well, but not for episodic migraine, based on its unique ability to inhibit the SNARE complex formation and the release of numerous potential mediators of migraine. However, despite the favorable figures on efficacy and tolerability of these compounds, the regulations, and particulars of different countries, regarding the structures and reimbursement of medical care, demonstrated different adhesion profiles of chosen populations to receive these emerging weapons against migraine-imposed suffering. This review addresses the use and characteristics of biological therapies used in migraine treatment.","PeriodicalId":472101,"journal":{"name":"Revista Headache Medicine","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136336285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The International Classification of Headache Disorders from the point of view of Thomas Kuhn: a reflection 从库恩的观点看国际头痛疾病分类:反思

Revista Headache Medicine Pub Date : 2023-09-30 DOI: 10.48208/headachemed.2023.26

Luis Gustavo Pagliarin, João Carlos Pegoraro de Almeida, Alcântara Ramos De Assis César

引用次数: 0

Preventive and abortive treatment of migraine with traditional drugs. The state of the art 传统药物对偏头痛的预防和流产治疗。最先进的技术

Revista Headache Medicine Pub Date : 2023-09-30 DOI: 10.48208/headachemed.2023.27

Raimundo Pereira Silva-Néto, Carla Jevoux, Abouch Krymchantowski

{"title":"Preventive and abortive treatment of migraine with traditional drugs. The state of the art","authors":"Raimundo Pereira Silva-Néto, Carla Jevoux, Abouch Krymchantowski","doi":"10.48208/headachemed.2023.27","DOIUrl":"https://doi.org/10.48208/headachemed.2023.27","url":null,"abstract":"IntroductionMigraine is a chronic neurological disease, with a prevalence of 15.2% in Brazil. It is 2.2 times more prevalent in women, predominantly in the 18-50 age group. Its pathophysiological mechanism is still not completely understood. Possibly headache attacks and symptoms are associated with cortical spreading depression, the trigeminovascular system, neurogenic inflammation, vasodilation and genetic vulnerability.ObjectiveThis is a narrative review of preventive and abortive treatment of migraine.CommentMigraine treatment is based on three pillars: patient education, treatment of the disease itself or prevention of attacks, and acute treatment of headache attacks. The therapeutic classes of traditional drugs used in migraine prevention are beta-blockers, tricyclic antidepressants, calcium channel antagonists or blockers, and anticonvulsant neuromodulators. Specific drugs used in the treatment of headache attacks are triptans or serotonergic 5-HT1B/1D receptor agonists, ditans or 5-HT1F receptor agonists, and gepants or CGRP receptor antagonists.ConclusionTraditional drugs used in the preventive or abortive treatment of migraine are considered to be effective. Through modulation of the disease mechanisms, there is a reduction in the frequency, intensity and duration of headache attacks, and also in the disability caused by the headache. All this to improve the quality of life of patients. The therapeutic classes of traditional drugs used in migraine prevention are beta-blockers, tricyclic antidepressants, antagonists or blockers of calcium channels and anticonvulsant neuromodulators. Specific drugs used in the treatment of headache attacks are triptans or serotonergic 5-HT1B/1D receptor agonists,ditans or 5-HT1F receptor agonists, and gepants or CGRP receptor antagonists.","PeriodicalId":472101,"journal":{"name":"Revista Headache Medicine","volume":"160 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136280536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of migraine in children and adolescents. The state of the art 儿童和青少年偏头痛的治疗。最先进的技术

Revista Headache Medicine Pub Date : 2023-09-30 DOI: 10.48208/headachemed.2023.30

Renato Arruda, Marco Antônio Arruda

{"title":"Treatment of migraine in children and adolescents. The state of the art","authors":"Renato Arruda, Marco Antônio Arruda","doi":"10.48208/headachemed.2023.30","DOIUrl":"https://doi.org/10.48208/headachemed.2023.30","url":null,"abstract":"IntroductionHeadaches and migraine are common in the pediatric population, being one of the most frequent symptoms reported in practice. Additionally, it is a considerably disabling condition, which brings significant burden and impairs several aspects of a child or adolescent's life, such as mental and physical health, executive functioning, school performance. Children and adolescents with migraine have higher risk of psychiatric comorbidities and psychosocial adjustment difficulties, which, in turn, compromise even more patient's well-functioning.ObjectiveThe present article provides the clinician with a straightforward and evidence-based approach to migraine treatment in this age group.CommentTreatment of migraine in children and adolescents requires a systematic and thorough approach. Clinicians should keep in mind the important burden migraine brings to a child's life, thus investigate, and properly manage comorbidities presented. Patient and parents' education is a meaningful part of the treatment. Moreover, non-pharmacological treatments, such as healthy lifestyle habits, behavioral interventions may also play beneficial roles. When preventive treatment is indicated, it should be tailored considering drug's profile of effectiveness and safety, as well as patient's comorbidities. Lack of evidence in this context must not translate in lack of action by the clinician, since there may be a relevant burden associated. Therefore, reasoning for the perspicacious clinician is of fundamental importance and may influence positively the outcomes.","PeriodicalId":472101,"journal":{"name":"Revista Headache Medicine","volume":"93 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136341287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The state of the art in treating patients with a dual diagnosis of chronic migraine and medication-overuse headache 治疗慢性偏头痛和药物滥用性头痛双重诊断患者的最新进展

Revista Headache Medicine Pub Date : 2023-09-30 DOI: 10.48208/headachemed.2023.29

Carla Jevoux, Abouch Krymchantowski, Raimundo Pereira Silva-Néto, Ana Gabriela Krymchantowski, Ervin Michelstaedter Cotrik

引用次数: 0

Prolotherapy in the treatment of chronic migraine — Case report 前列腺素治疗慢性偏头痛1例报告

Revista Headache Medicine Pub Date : 2023-09-18 DOI: 10.48208/headachemed.2023.23

Ítallo Bernardo Souto, Fernanda Fabiola Santos de Lima, Vanessa Arapiraca Ferreira, Camila Emily Batista Lopes, Laylla Gabrielly Lacerda Sousa, Victor Egypto Pereira, Luiz Severo Bem Junior

{"title":"Prolotherapy in the treatment of chronic migraine — Case report","authors":"Ítallo Bernardo Souto, Fernanda Fabiola Santos de Lima, Vanessa Arapiraca Ferreira, Camila Emily Batista Lopes, Laylla Gabrielly Lacerda Sousa, Victor Egypto Pereira, Luiz Severo Bem Junior","doi":"10.48208/headachemed.2023.23","DOIUrl":"https://doi.org/10.48208/headachemed.2023.23","url":null,"abstract":"IntroductionChronic migraine is a socioeconomic and individual burden since it is the largest cause of disability in people under 50 years of age. Although there are several prophylactic drug alternatives, some patients are vulnerable to refractoriness with significant damage to their quality of life. Prolotherapy, a subcutaneous injection of dextrose in peripheral nerves, advocates as a promising tool in the management of this pathology.Case reportA patient with refractory chronic migraine to drug therapy who was submitted to neurofascial prolotherapy. Weekly administration of a 2 ml solution of 1% ropivacaine and 10% glucose in the head peripheral nerves for 6 weeks. Reduced disability and frequency of migraine attacks for a period of 8 weeks after interventions.ConclusionProlotherapy proved itself to be a notable technique for reducing the number of days in a month that a patient with refractory chronic migraine to standardized therapy has had headaches. However, placebo group studies are needed to determine the efficacy of the procedure.","PeriodicalId":472101,"journal":{"name":"Revista Headache Medicine","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135110205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Paroxysmal Hemicrania-Trigeminal Neuralgia (PH-Tic) syndrome with no structural lesion in a Brazilian woman: the first case-report 阵发性偏头痛-三叉神经痛(PH-Tic)综合征，无结构性病变的巴西妇女:第一例病例报告

Revista Headache Medicine Pub Date : 2023-09-18 DOI: 10.48208/headachemed.2023.20

Thales Pardini Fagundes, Matheus Compart Hemerly, Alison Mangolin, Ellen Silva de Carvalho, Natália de Oliveira Silva, Roberto Satler Cetlin, Fabíola Dach

{"title":"Paroxysmal Hemicrania-Trigeminal Neuralgia (PH-Tic) syndrome with no structural lesion in a Brazilian woman: the first case-report","authors":"Thales Pardini Fagundes, Matheus Compart Hemerly, Alison Mangolin, Ellen Silva de Carvalho, Natália de Oliveira Silva, Roberto Satler Cetlin, Fabíola Dach","doi":"10.48208/headachemed.2023.20","DOIUrl":"https://doi.org/10.48208/headachemed.2023.20","url":null,"abstract":"IntroductionIn Brazil there is only one case report of a patient diagnosed with Paroxysmal Hemicrania-Trigeminal (PH-Tic) syndrome reported, however it was observed in a patient with Chiari I malformation.ObjectiveHere, we describe the first case of primary PH-Tic syndrome in the country.MethodCase report. CARE guideline was used to guide the structuring of this article. This case report was approved by the ethics committee and has been registered under the protocol number 70705623.7.0000.5440 on “Plataforma Brasil”.ResultsA 72-year-old woman with a five-month history of headaches was admitted at our headache outpatient clinic. The pain was sharp, intense, localized in the periorbital and left temporal regions. Blood counts, liver, renal and thyroid function were normal, as well as brain magnetic resonance imaging. Despite using carbamazepine, the patient had pain in only the left side of the face. Indomethacin was added until the dose of 100 mg a day and resulted in improvement of headache frequency.ConclusionPH-Tic should be hypothesized in patients with short-lasting headaches associated with facial pain that partially improve with carbamazepine or indomethacin.","PeriodicalId":472101,"journal":{"name":"Revista Headache Medicine","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135152696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Headache attributed to spontaneous intracranial hypotension and associated possible causes 自发性颅内低血压引起的头痛及其可能的原因

Revista Headache Medicine Pub Date : 2023-09-18 DOI: 10.48208/headachemed.2023.14

Marcelo Moraes Valença

引用次数: 0

Prevalência de enxaqueca em pacientes com fibromialgia 纤维肌痛患者偏头痛的患病率

Revista Headache Medicine Pub Date : 2023-09-14 DOI: 10.48208/headachemed.2023.19

Lucas Dias Miguel Moreira Vieira, Aléxia Michelle Castro Florisbelo, Ana Flávia Ribeiro, Bianca Silva De Carvalho, Isabela Maria Lopes Campos, Patrícia Daher Neves Magri, Filipe Augusto Carvalho De Paula, Mauro Jurno

{"title":"Prevalência de enxaqueca em pacientes com fibromialgia","authors":"Lucas Dias Miguel Moreira Vieira, Aléxia Michelle Castro Florisbelo, Ana Flávia Ribeiro, Bianca Silva De Carvalho, Isabela Maria Lopes Campos, Patrícia Daher Neves Magri, Filipe Augusto Carvalho De Paula, Mauro Jurno","doi":"10.48208/headachemed.2023.19","DOIUrl":"https://doi.org/10.48208/headachemed.2023.19","url":null,"abstract":"ObjetivoAvaliar a prevalência de enxaqueca em pacientes com fibromialgia e os impactos dessas comorbidades no cotidiano dos pacientes.MétodosQuestionários foram aplicados a pacientes com fibromialgia. Os questionários foram aplicados por meio de link de aplicativo Google Forms e presencialmente, impressos. Usamos FIQ, PHQ-9 e enxaqueca ID. E para pacientes com enxaqueca ID positiva, aplicamos o Midas posteriormente.ResultadosForam recrutados 70 pacientes com fibromialgia, idade de 47,31 ± 14,5 anos. Sessenta e cinco (92,86%) eram do sexo feminino e 5 (7,14%) do sexo masculino. Obtivemos uma prevalência de 60% (n = 42) de enxaqueca associada à fibromialgia. Entre as variáveis analisadas, a gravidade da depressão (p = 0,007), a gravidade agregada da depressão (p = 0,004) e o impacto da fibromialgia (p = 0,008) foram significativamente associadas. Entre os pacientes com enxaqueca, a grande maioria, 34/42 (80,95%), foi classificada como portadora de incapacidade grave.ConclusãoExiste uma elevada prevalência de enxaqueca em pacientes com fibromialgia que tem impacto associado na vida dos pacientes, o que torna necessário o manejo clínico e psicossocial desses pacientes.","PeriodicalId":472101,"journal":{"name":"Revista Headache Medicine","volume":"47 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134971099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The International Classification of Headache Disorders from the point of view of Thomas Kuhn: a reflection 从库恩的观点看国际头痛疾病分类:反思

Revista Headache Medicine Pub Date : 2023-09-14 DOI: 10.48208/headachemed.2023.25

Luis Gustavo Pagliarin, João Carlos Pegoraro de Almeida, Alcântara Ramos De Assis César

{"title":"The International Classification of Headache Disorders from the point of view of Thomas Kuhn: a reflection","authors":"Luis Gustavo Pagliarin, João Carlos Pegoraro de Almeida, Alcântara Ramos De Assis César","doi":"10.48208/headachemed.2023.25","DOIUrl":"https://doi.org/10.48208/headachemed.2023.25","url":null,"abstract":"Headaches are characterized by a sensation of discomfort or pain in the cephalicregion. Due to the large number of types and subtypes of headaches, the standardization of their approach is necessary through the International Classification ofHeadache Disorders (ICHD), a document that is currently in its 3rd edition (ICHD-3).The evolution of the ICHD follows the hypothetical-deductive model of science basedon Karl Popper's philosophy, which has a strong presence in the health sciences.The classification of headaches has evolved over time, incorporating and removingcriteria, reflecting the need to adapt the classification to constantly evolving scientificand clinical demands. However, some changes can generate discrepancies betweenclinical practice and the elaborated diagnostic tools. In this context, this article reflectson whether it would be advantageous to return to old principles and foundations ofobsolete classifications. The criterion of osmophobia, which is no longer in use inICHD-3, is highlighted. This reflection can be developed following Thomas Kuhn's(1922-1996) view on science. In his main work, \"The Structure of Scientific Revolutions\"(1962), Kuhn proposes a three-stage model for science: the adoption of a paradigm,normal science, and a period of crisis. Kuhn also proposes the principle of incommensurability to understand the limitations and complexities of science. The applicationof this principle allows headache specialists to recognize that different approachesto headache classification have their own limitations and complexities, encouragingthem to consider a variety of perspectives, paradigms, and theories in approachingclinical cases and conducting scientific studies. An integrative approach that combinesPopper's hypothetical-deductive model with Kuhn's principle of incommensurabilityallows headache specialists to have a broader and more critical understanding ofheadache classifications.","PeriodicalId":472101,"journal":{"name":"Revista Headache Medicine","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134971096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0